Actithera a r\u00e9uni 75,5 millions de dollars dans le cadre d’un financement de s\u00e9rie A sursouscrit pour soutenir le d\u00e9veloppement clinique de son principal traitement par radioligand ciblant la prot\u00e9ine d’activation des fibroblastes (FAP) et pour \u00e9largir son pipeline de d\u00e9couverte de m\u00e9dicaments.<\/p>\n
Le financement a \u00e9t\u00e9 co-dirig\u00e9 par M Ventures, Hadean Ventures, Sofinnova Partners et 4BIO Capital, avec le soutien suppl\u00e9mentaire de Bioqube Ventures, Surveyor Capital, Arkin Bio Ventures II et d’autres.<\/p>\n
Bas\u00e9e \u00e0 Oslo et Cambridge, Actithera d\u00e9veloppe une plateforme de traitement par radioligand de nouvelle g\u00e9n\u00e9ration ax\u00e9e sur la r\u00e9tention sp\u00e9cifique du m\u00e9dicament dans les tumeurs. Sa conception en trois piliers int\u00e8gre la conception rationnelle de m\u00e9dicaments et la radiochimie, ciblant un temps de r\u00e9sidence plus long dans la tumeur tout en r\u00e9duisant l’exposition syst\u00e9mique.<\/p>\n
La plateforme a produit un candidat radioligand ciblant FAP avec un potentiel de meilleure cat\u00e9gorie. Il atteint une sp\u00e9cificit\u00e9 tumorale forte et un profil pharmacocin\u00e9tique optimal, offrant une pr\u00e9cision, une s\u00e9curit\u00e9 et un effet th\u00e9rapeutique am\u00e9lior\u00e9s.<\/p>\n
Le Dr Andreas Goutopoulos, fondateur et PDG, apporte plus de 25 ans d’exp\u00e9rience et a pr\u00e9c\u00e9demment dirig\u00e9 les efforts de d\u00e9couverte chez EMD Serono. En tant qu’entrepreneur en r\u00e9sidence chez M Ventures, il a soutenu plusieurs biotechnologies ax\u00e9es sur l’oncologie.<\/p>\n
Le Dr Goutopoulos a d\u00e9clar\u00e9 : \u00ab Ce financement de s\u00e9rie A sursouscrit, soutenu par un syndicat d’investisseurs v\u00e9ritablement mondial et exp\u00e9riment\u00e9, est une forte validation de notre approche. Nous concevons nos radioconjugu\u00e9s pour une r\u00e9tention prolong\u00e9e au sein des tumeurs, les rendant id\u00e9alement adapt\u00e9s aux radionucl\u00e9ides \u00e0 plus longue dur\u00e9e de vie et offrant finalement des sch\u00e9mas posologiques plus pratiques et une efficacit\u00e9 et une s\u00e9curit\u00e9 am\u00e9lior\u00e9es pour les patients. \u00bb<\/p>\n
Karl Naegler, nouveau membre du conseil d’administration et partenaire chez Sofinnova Partners, a d\u00e9clar\u00e9 : \u00ab Actithera applique la discipline des grandes soci\u00e9t\u00e9s pharmaceutiques \u00e0 un domaine \u00e9mergent au potentiel \u00e9norme. Ses traitements par radioligand repr\u00e9sentent un changement significatif en oncologie. \u00bb<\/p>\n
Les autres membres du conseil d’administration incluent Roger Franklin de Hadean Ventures, Therese Liechtenstein de 4BIO Capital et Debbie Dumont de Bioqube Ventures. Ils rejoignent le membre actuel du conseil d’administration Noga Yerushalmi de M Ventures.<\/p>\n","protected":false},"excerpt":{"rendered":"
Actithera a r\u00e9uni 75,5 millions de dollars dans le cadre d’un financement de s\u00e9rie A sursouscrit pour soutenir le d\u00e9veloppement clinique de son principal traitement par radioligand ciblant la prot\u00e9ine d’activation des fibroblastes (FAP) et pour \u00e9largir son pipeline de d\u00e9couverte de m\u00e9dicaments. Le financement a \u00e9t\u00e9 co-dirig\u00e9 par M Ventures, Hadean Ventures, Sofinnova Partners […]<\/p>\n","protected":false},"author":1,"featured_media":69696,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[684],"tags":[],"class_list":["post-69695","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelles-pharmaceutiques"],"_links":{"self":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/comments?post=69695"}],"version-history":[{"count":1,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69695\/revisions"}],"predecessor-version":[{"id":69708,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69695\/revisions\/69708"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/media\/69696"}],"wp:attachment":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/media?parent=69695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/categories?post=69695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/tags?post=69695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}